JP2022531970A5 - - Google Patents

Info

Publication number
JP2022531970A5
JP2022531970A5 JP2021567815A JP2021567815A JP2022531970A5 JP 2022531970 A5 JP2022531970 A5 JP 2022531970A5 JP 2021567815 A JP2021567815 A JP 2021567815A JP 2021567815 A JP2021567815 A JP 2021567815A JP 2022531970 A5 JP2022531970 A5 JP 2022531970A5
Authority
JP
Japan
Prior art keywords
group
cancer
alkyl
independently selected
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021567815A
Other languages
English (en)
Japanese (ja)
Other versions
JP7656547B2 (ja
JP2022531970A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/032904 external-priority patent/WO2020232256A1/en
Publication of JP2022531970A publication Critical patent/JP2022531970A/ja
Publication of JP2022531970A5 publication Critical patent/JP2022531970A5/ja
Application granted granted Critical
Publication of JP7656547B2 publication Critical patent/JP7656547B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021567815A 2019-05-15 2020-05-14 Pd-l1疾患治療用のトリアリール化合物 Active JP7656547B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962848114P 2019-05-15 2019-05-15
US62/848,114 2019-05-15
PCT/US2020/032904 WO2020232256A1 (en) 2019-05-15 2020-05-14 Triaryl compounds for treatment of pd-l1 diseases

Publications (3)

Publication Number Publication Date
JP2022531970A JP2022531970A (ja) 2022-07-12
JP2022531970A5 true JP2022531970A5 (enExample) 2023-05-19
JP7656547B2 JP7656547B2 (ja) 2025-04-03

Family

ID=73289294

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021567815A Active JP7656547B2 (ja) 2019-05-15 2020-05-14 Pd-l1疾患治療用のトリアリール化合物

Country Status (14)

Country Link
US (2) US11266643B2 (enExample)
EP (1) EP3968996A4 (enExample)
JP (1) JP7656547B2 (enExample)
KR (1) KR20220009420A (enExample)
CN (1) CN114340633B (enExample)
AU (2) AU2020276277B2 (enExample)
BR (1) BR112021022659A2 (enExample)
CA (1) CA3139526A1 (enExample)
IL (1) IL287843B2 (enExample)
MA (1) MA55974A (enExample)
MX (1) MX2021013819A (enExample)
SG (1) SG11202112310TA (enExample)
WO (1) WO2020232256A1 (enExample)
ZA (1) ZA202108626B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10639284B2 (en) 2016-06-27 2020-05-05 Chemocentryx, Inc. Immunomodulator compounds
US10919852B2 (en) 2017-07-28 2021-02-16 Chemocentryx, Inc. Immunomodulator compounds
US10392405B2 (en) 2017-08-08 2019-08-27 Chemocentryx, Inc. Macrocyclic immunomodulators
US10568874B2 (en) 2018-02-22 2020-02-25 Chemocentryx, Inc. Indane-amines as PD-L1 antagonists
WO2020232256A1 (en) * 2019-05-15 2020-11-19 Chemocentryx, Inc. Triaryl compounds for treatment of pd-l1 diseases
WO2020257549A2 (en) * 2019-06-20 2020-12-24 Chemocentryx, Inc. Compounds for treatment of pd-l1 diseases
BR112021025888A2 (pt) 2019-07-10 2022-04-26 Chemocentryx Inc Indanos como inibidores de pd-l1
ES3064674T3 (en) 2019-10-16 2026-04-28 Chemocentryx Inc Heteroaryl-biphenyl amines for the treatment of pd-l1 diseases
JP7736678B2 (ja) * 2019-10-16 2025-09-09 ケモセントリックス,インコーポレイティド Pd-l1疾患の処置のためのヘテロアリール-ビフェニルアミド
CN112812113B (zh) * 2019-11-15 2022-09-20 杭州和正医药有限公司 免疫调节化合物、组合物及其应用
WO2021136354A1 (zh) * 2020-01-03 2021-07-08 上海翰森生物医药科技有限公司 联苯类衍生物抑制剂、其制备方法和应用
MX2022016554A (es) * 2020-06-23 2023-04-10 Chemocentryx Inc Métodos de tratamiento del cáncer mediante derivados heteroaril-bifenil-amida.
WO2022152316A1 (zh) * 2021-01-18 2022-07-21 南京明德新药研发有限公司 联苯衍生物及其应用
EP4337202A4 (en) 2021-06-18 2025-04-02 Aligos Therapeutics, Inc. METHODS AND COMPOSITIONS FOR TARGETING PD-L1
CA3240263A1 (en) 2021-12-09 2023-06-15 Daniel L. Flynn Raf kinase inhibitors and methods of use thereof
EP4448512A4 (en) 2021-12-16 2025-11-19 Aligos Therapeutics Inc METHODS AND COMPOSITIONS FOR TARGETING PD-L1
CN115010658B (zh) * 2022-05-11 2023-06-27 南方医科大学 一种化合物及其制备方法与应用
WO2024018403A1 (en) * 2022-07-21 2024-01-25 Arbutus Biopharma Corporation Substituted imidazoamide compounds, and methods using same
WO2024134466A1 (en) * 2022-12-21 2024-06-27 Arbutus Biopharma Corporation Substituted arylamine compounds, substituted heteroarylamine compounds, and methods using same
AU2024209359A1 (en) * 2023-01-20 2025-07-03 Aligos Therapeutics, Inc. Methods and compositions for targeting pd-l1
WO2025015063A1 (en) * 2023-07-13 2025-01-16 Aligos Therapeutics, Inc. Methods and compositions for targeting pd-l1
CN116903489B (zh) * 2023-07-14 2025-09-02 北京汉典制药有限公司 三联苯类化合物、其制备方法及其应用
PL449370A1 (pl) * 2024-07-26 2026-02-02 Uniwersytet Jagielloński Nowe pochodne N-terfenylopikolinamidu oraz ich zastosowanie

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9604926D0 (en) * 1996-03-08 1996-05-08 Sandoz Ltd Organic compounds
EP2418202B1 (en) 2006-03-31 2014-01-29 Novartis AG (4-[4-[5-(substituted amino)-pyridin-2-yl]phenyl]-cyclohexyl)-acetic acid derivatives as DGAT inhibitors
ES2333539T3 (es) 2006-04-21 2010-02-23 Cellzome Limited Derivados de terfenilo para el tratamiento de la enfermedad de alzheimer.
WO2008008059A1 (en) 2006-07-12 2008-01-17 Locus Pharmaceuticals, Inc. Anti-cancer agents ans uses thereof
WO2011082400A2 (en) 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
MX368257B (es) 2011-08-01 2019-09-26 Genentech Inc Antagonistas de unión al eje pd-1e inhibidores de mek y sus usos en el tratamiento de cáncer.
SG11201402004YA (en) 2011-11-14 2014-05-29 Cephalon Inc Uracil derivatives as axl and c-met kinase inhibitors
EP2788000B1 (en) 2011-12-06 2018-05-30 Merck Sharp & Dohme Corp. Pyrrolopyrimidines as janus kinase inhibitors
CN105705489B (zh) 2013-09-04 2019-04-26 百时美施贵宝公司 用作免疫调节剂的化合物
EA029661B1 (ru) 2013-09-06 2018-04-30 Ауриген Дискавери Текнолоджиз Лимитед Производные 1,3,4-оксадиазола и 1,3,4-тиадиазола в качестве иммуномодуляторов
HUE038169T2 (hu) 2013-09-06 2018-09-28 Aurigene Discovery Tech Ltd 1,2,4-Oxadiazol származékok mint immunomodulátorok
US9850225B2 (en) 2014-04-14 2017-12-26 Bristol-Myers Squibb Company Compounds useful as immunomodulators
JP6767096B2 (ja) 2014-12-11 2020-10-14 リティックス バイオファーマ エイエス 免疫チェックポイント阻害剤の組み合わせ
BR112017019307A2 (pt) * 2015-03-10 2018-05-02 Aurigene Discovery Technologies Limited compostos de 1,3,4-oxadiazol 3-substituído e tiadiazol como imunomoduladores
NL1041468B1 (en) 2015-09-08 2017-03-22 Bosch Gmbh Robert Metal ring component of a drive belt for a continuously variable transmisson.
US10745382B2 (en) 2015-10-15 2020-08-18 Bristol-Myers Squibb Company Compounds useful as immunomodulators
WO2017070089A1 (en) 2015-10-19 2017-04-27 Incyte Corporation Heterocyclic compounds as immunomodulators
SG10202004618TA (en) 2015-11-19 2020-06-29 Incyte Corp Heterocyclic compounds as immunomodulators
MA44075A (fr) 2015-12-17 2021-05-19 Incyte Corp Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1
AU2016379372A1 (en) 2015-12-22 2018-08-02 Incyte Corporation Heterocyclic compounds as immunomodulators
EP3190103A1 (en) 2016-01-08 2017-07-12 Rijksuniversiteit Groningen Inhibitors of the pd-1/pd-l1 protein/protein interaction
EP3439658B1 (en) 2016-04-04 2021-11-24 ChemoCentryx, Inc. Soluble c5ar antagonists
AR108396A1 (es) 2016-05-06 2018-08-15 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
WO2017202275A1 (zh) 2016-05-23 2017-11-30 中国医学科学院药物研究所 溴代苄醚衍生物、及其制法和药物组合物与用途
WO2017205464A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
HUE060256T2 (hu) 2016-06-20 2023-02-28 Incyte Corp Heterociklusos vegyületek mint immunmodulátorok
US10639284B2 (en) 2016-06-27 2020-05-05 Chemocentryx, Inc. Immunomodulator compounds
KR102482673B1 (ko) 2016-07-05 2022-12-30 광저우 맥시노벨 파마수티컬스 씨오., 엘티디. 방향족 아세틸렌 또는 방향족 에틸렌계 화합물, 그의 중간체, 제조 방법, 약물 조성물 및 용도
EA201990221A1 (ru) 2016-07-08 2019-06-28 Бристол-Маерс Сквибб Компани 1,3-дигидроксифенильные производные, применимые в качестве иммуномодуляторов
EP3484866B1 (en) 2016-07-14 2022-09-07 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018044783A1 (en) 2016-08-29 2018-03-08 Incyte Corporation Heterocyclic compounds as immunomodulators
US10144706B2 (en) 2016-09-01 2018-12-04 Bristol-Myers Squibb Company Compounds useful as immunomodulators
WO2018045142A1 (en) 2016-09-02 2018-03-08 Polaris Pharmaceuticals, Inc. Immune checkpoint inhibitors, compositions and methods thereof
EP3558970B1 (en) 2016-12-20 2021-09-01 Bristol-Myers Squibb Company Compounds useful as immunomodulators
WO2018119263A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds derivatives as pd-l1 internalization inducers
ES2874756T3 (es) 2016-12-22 2021-11-05 Incyte Corp Derivados de triazolo[1,5-A]piridina como inmunomoduladores
US20180179202A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
JP7101678B2 (ja) 2016-12-22 2022-07-15 インサイト・コーポレイション 免疫調節剤としての複素環式化合物
WO2018119221A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Pyridine derivatives as immunomodulators
LT3558990T (lt) 2016-12-22 2022-12-27 Incyte Corporation Tetrahidroimidazo[4,5-c]piridino dariniai kaip pd-l1 internalizavimo induktoriai
CN106674136B (zh) 2016-12-23 2019-07-02 中国医科大学 嘧啶类抗肿瘤化合物及其制备方法
EP3564237A4 (en) 2016-12-29 2020-06-10 Shenzhen Chipscreen Biosciences Co., Ltd. UREA COMPOUND AND PRODUCTION METHOD AND USE THEREOF
CN108395443B (zh) 2017-02-04 2021-05-04 广州丹康医药生物有限公司 抑制程序性死亡受体配体1的环状化合物及其用途
CN110461829B (zh) 2017-03-27 2023-02-28 百时美施贵宝公司 作为免疫调节剂的取代的异喹啉衍生物
BR102018007822A2 (pt) * 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
TW201841896A (zh) 2017-04-26 2018-12-01 大陸商南京聖和藥業股份有限公司 作為pd—l1抑制劑的雜環類化合物
CN108863963B (zh) 2017-05-08 2022-05-27 南京圣和药物研发有限公司 作为pd-l1抑制剂的杂环类化合物
WO2019008156A1 (en) * 2017-07-07 2019-01-10 Rijksuniversiteit Groningen INHIBITORS OF PROTEIN / PROTEIN INTERACTION PD-1 / PD-L1
US10919852B2 (en) 2017-07-28 2021-02-16 Chemocentryx, Inc. Immunomodulator compounds
US10392405B2 (en) 2017-08-08 2019-08-27 Chemocentryx, Inc. Macrocyclic immunomodulators
EP3669872A4 (en) 2017-08-18 2021-05-05 Shanghai Ennovabio Pharmaceuticals Co., Ltd. FORMYL PYRIDINE DERIVATIVE WITH PD-L1 INHIBITORING EFFECT, MANUFACTURING METHOD FOR IT AND USE THEREOF
CA3293051A1 (en) 2017-09-25 2026-03-02 Chemocentryx, Inc. Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitor
US20190275015A1 (en) 2017-09-25 2019-09-12 Chemocentryx, Inc. Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitor
CN111051332B (zh) 2017-10-03 2024-09-06 百时美施贵宝公司 免疫调节剂
CN109665968B (zh) 2017-10-16 2022-02-22 四川科伦博泰生物医药股份有限公司 并环化合物及其制备方法和用途
CN109678796B (zh) 2017-10-19 2023-01-10 上海长森药业有限公司 Pd-1/pd-l1小分子抑制剂及其制备方法和用途
CN109721527B (zh) 2017-10-27 2024-03-12 广州丹康医药生物有限公司 一种新型抗pd-l1化合物、其应用及含其的组合物
US11629135B2 (en) 2017-11-06 2023-04-18 Jubilant Prodell Llc Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation
CN109956898B (zh) 2017-12-22 2021-03-26 上海海雁医药科技有限公司 免疫调节剂及其制法与医药上的用途
CN109988144B (zh) 2017-12-29 2024-07-05 广州再极医药科技有限公司 芳香乙烯或芳香乙基类衍生物、其制备方法、中间体、药物组合物及应用
KR102738303B1 (ko) 2018-01-23 2024-12-03 브리스톨-마이어스 스큅 컴퍼니 면역조정제로서 유용한 2,8-디아실-2,8-디아자스피로[5.5]운데칸 화합물
WO2019149183A1 (zh) 2018-02-05 2019-08-08 上海和誉生物医药科技有限公司 一种联芳基衍生物、其制备方法和在药学上的应用
CR20200347A (es) 2018-02-13 2020-09-23 Gilead Sciences Inc Inhibidores pd-1/pd-l1
US10568874B2 (en) 2018-02-22 2020-02-25 Chemocentryx, Inc. Indane-amines as PD-L1 antagonists
CN112041312A (zh) 2018-03-01 2020-12-04 百时美施贵宝公司 用作免疫调节剂的化合物
CN111788193B (zh) 2018-03-13 2023-04-04 广东东阳光药业有限公司 Pd-1/pd-l1类小分子抑制剂及其在药物中的应用
MX2020009517A (es) 2018-03-13 2021-01-20 Jubilant Prodel LLC Compuestos biciclicos como inhibidores de la interaccion/activacio n de pdl/pd-l1.
US12083118B2 (en) * 2018-03-29 2024-09-10 Arbutus Biopharma Corporation Substituted 1,1′-biphenyl compounds, analogues thereof, and methods using same
SMT202500157T1 (it) 2018-03-30 2025-05-12 Incyte Corp Composti eterociclici come immunomodulatori
JP2021520342A (ja) 2018-04-03 2021-08-19 ベータ ファーマシューティカルズ カンパニー リミテッド 免疫調節物質、組成物及びそれらの方法
TWI712412B (zh) 2018-04-19 2020-12-11 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
HUE061503T2 (hu) 2018-05-11 2023-07-28 Incyte Corp Tetrahidro-imidazo[4,5-C]piridin-származékok mint PD-L1 immunmodulátorok
TWI798463B (zh) 2018-07-11 2023-04-11 大陸商上海和譽生物醫藥科技有限公司 免疫抑制劑及其製備方法和在藥學上的應用
CN112384500B (zh) 2018-07-12 2024-05-14 贝达药业股份有限公司 免疫调节剂及其组合物和制备方法
SG11202012425QA (en) 2018-07-13 2021-01-28 Gilead Sciences Inc Pd-1/pd-l1 inhibitors
CN112566900B (zh) 2018-07-19 2024-04-26 贝达药业股份有限公司 免疫调节剂及其组合物和制备方法
US20210300909A1 (en) 2018-07-19 2021-09-30 Betta Pharmaceuticals Co., Ltd Immunomodulators, compositions and methods thereof
US20210347785A1 (en) 2018-08-01 2021-11-11 Shanghai Ennovabio Pharmaceuticals Co., Ltd. Preparation and application of aromatic compound having immunoregulatory function
US20210236476A1 (en) 2018-08-29 2021-08-05 Chemocentryx, Inc. Methods of treating cancer with small molecule pd-l1 inhibitors
CN109336857A (zh) 2018-11-13 2019-02-15 南方医科大学 一种含取代联苯的黄酮及其应用
CN109438263A (zh) 2018-11-28 2019-03-08 南方医科大学 一种含取代联苯的萘及其应用
CN109503546A (zh) 2019-01-10 2019-03-22 南方医科大学 一种间苯二酚二苯甲醚及其应用
CN109776377B (zh) 2019-02-01 2021-08-24 沈阳药科大学 吲哚啉类化合物及其制备方法和应用
US20200297708A1 (en) 2019-03-19 2020-09-24 Chemocentryx, Inc. Combination Therapy Using a Chemokine Receptor 2 (CCR2) Antagonist and a PD-1 and/or PD-L1 Inhibitor
CN109776445B (zh) 2019-03-28 2022-12-06 中国药科大学 苯并噁二唑类化合物及其制备方法和医药用途
WO2020232256A1 (en) 2019-05-15 2020-11-19 Chemocentryx, Inc. Triaryl compounds for treatment of pd-l1 diseases
CN110200959A (zh) 2019-05-30 2019-09-06 天津科技大学 一种黄酮类化合物的应用
CN110128415B (zh) 2019-05-31 2022-03-25 沈阳药科大学 用作免疫调节剂的吲哚啉类化合物及其制备方法
WO2020257549A2 (en) 2019-06-20 2020-12-24 Chemocentryx, Inc. Compounds for treatment of pd-l1 diseases
BR112021025888A2 (pt) 2019-07-10 2022-04-26 Chemocentryx Inc Indanos como inibidores de pd-l1
TWI775182B (zh) 2019-10-16 2022-08-21 美商莫菲克醫療股份有限公司 抑制人類整合素αβ
JP7736678B2 (ja) 2019-10-16 2025-09-09 ケモセントリックス,インコーポレイティド Pd-l1疾患の処置のためのヘテロアリール-ビフェニルアミド
ES3064674T3 (en) 2019-10-16 2026-04-28 Chemocentryx Inc Heteroaryl-biphenyl amines for the treatment of pd-l1 diseases
MX2022016554A (es) 2020-06-23 2023-04-10 Chemocentryx Inc Métodos de tratamiento del cáncer mediante derivados heteroaril-bifenil-amida.

Similar Documents

Publication Publication Date Title
JP2022531970A5 (enExample)
JP2022536845A5 (enExample)
JP2025170244A5 (enExample)
JP2022551973A5 (enExample)
JP2022551972A5 (enExample)
JP5756518B2 (ja) 複素環アルキニルベンゼン化合物と、その医療用組成物および使用
US9085540B2 (en) Pyrazinecarboxamide compound
JP5714573B2 (ja) キヌレニン産生抑制作用を有する含窒素複素環化合物
CN118317774A (zh) 包含喹唑啉化合物的药物组合物
JP6514703B2 (ja) キナーゼインヒビターとして有用な尿素誘導体
CN113316574A (zh) Shp2抑制剂及其应用
CN111247152B (zh) 作为激酶抑制剂的环状亚氨基嘧啶衍生物
CN103402519B (zh) 肿瘤治疗剂
JP2023507669A (ja) ピリド[3,4-d]ピリミジン誘導体およびこれを含む治療用薬学組成物
CN104039798A (zh) 具有蛋白激酶抑制活性的噻吩并[3,2-d]嘧啶衍生物
WO2020119739A1 (zh) 2-氨基嘧啶类化合物及其应用
CN106029646A (zh) 嘧啶-2,4-二胺衍生物和含有该衍生物作为活性成分的抗癌药物组合物
CN103214480B (zh) 吡唑并吡啶炔苯类化合物及其药用组合物和应用
JP2022539830A5 (enExample)
CN110818641B (zh) 哒嗪-3-甲酰胺类化合物、其制备方法及其在医药学上的应用
US10085989B2 (en) Compounds and compositions for the treatment of parasitic diseases
JP2009537606A5 (enExample)
TWI691500B (zh) 作為tyro3、axl和mertk(tam)家族受體酪胺酸激酶抑制劑之雜環化合物
WO2022032484A1 (zh) 哒嗪-3-甲酰胺类化合物、其制备方法及其在医药学上的应用
JP2024539633A5 (enExample)